Humanwell PuraCap Pharmaceuticals (Wuhan) Co., Ltd
FDA inspection history in Wuhan, China, 2019
- 1
- Form 483
Every document, by year
- Form 483
2019: one Form 483.
The story so far
Built from the dates and citations on the documents themselves.
- 2019One Form 483, at Wuhan, China.
Cited most
Across all Humanwell PuraCap Pharmaceuticals (Wuhan) Co. observations on file
- 21 CFR 211.180General requirements1
- 21 CFR 211.188Batch production and control records1
The complete Humanwell PuraCap Pharmaceuticals (Wuhan) Co. file.
All 1 documents as original PDFs. For supplier audits, diligence and inspection prep.
Sites
Wuhan, China
One Form 483 · 2019 · 2 observations
Latest: Form 483, Jun 14, 2019 →
Documents
1 on file, newest first| Date | Document | Location | Observations | Price |
|---|---|---|---|---|
| 2019-06-14 | 483 Form 483 | Wuhan, China | 2 | $99 |
FEI number 3010163919 · most recent document Jun 14, 2019
About Humanwell PuraCap Pharmaceuticals (Wuhan) Co., Ltd
How many FDA Form 483s has Humanwell PuraCap Pharmaceuticals (Wuhan) Co., Ltd received?
FDA Intel has 1 Form 483 on file for Humanwell PuraCap Pharmaceuticals (Wuhan) Co., Ltd; the most recent is dated Jun 14, 2019.
When was Humanwell PuraCap Pharmaceuticals (Wuhan) Co., Ltd last inspected by FDA?
The most recent FDA inspection document on file for Humanwell PuraCap Pharmaceuticals (Wuhan) Co., Ltd is a Form 483 dated Jun 14, 2019, for the site in Wuhan, China.
What did FDA cite at Humanwell PuraCap Pharmaceuticals (Wuhan) Co., Ltd?
The regulations cited most in the observations on file for Humanwell PuraCap Pharmaceuticals (Wuhan) Co., Ltd are 21 CFR 211.180 (General requirements), 1 time; 21 CFR 211.188 (Batch production and control records), 1 time.